An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy

ESMO Open

article

C. Blaye¹  É. Darbo³  M. Debled¹  V. Brouste⁴  V. Vélasco⁵  C. Pinard⁶  N. Larmonier²  I. Pellegrin⁷  A. Tarricone⁷  M. Arnedos¹  J. Commeny⁹  H. Bonnefoi¹  C. Larmonier⁵  G. MacGrogan³ 

[1] Department of Medical Oncology, Institut Bergonié;Univ. Bordeaux;Univ. Bordeaux, INSERM U1218, ACTION Laboratory;Departments of Clinical Research and Medical Information;Biopathology, Institut Bergonié;Pathology Laboratory, University Hospital of Martinique;Service d’Immunologie et Immunogénétique, University Hospital of Bordeaux;Centre de Ressources Biologiques Plurithématique, University Hospital of Bordeaux;Department of Surgery, Institut Bergonié

关键词: triple-negative breast cancer;    residual disease;    tumor immune microenvironment;    transcriptomic signature;   

DOI  :  10.1016/j.esmoop.2022.100502

学科分类：社会科学、人文和艺术（综合）

来源: BMJ Publishing Group

【 摘 要 】

Background When triple-negative breast cancer (TNBC) patients have residual disease after neoadjuvant chemotherapy (NACT), they have a high risk of metastatic relapse. With immune infiltrate in TNBC being prognostic and predictive of response to treatment, our aim was to develop an immunologic transcriptomic signature using post-NACT samples to predict relapse.Materials and methods We identified 115 samples of residual tumors from post-NACT TNBC patients. We profiled the expression of 770 genes related to cancer microenvironment using the NanoString PanCancer IO360 panel to develop a prognostic transcriptomic signature, and we describe the immune microenvironments of the residual tumors.Results Thirty-eight (33%) patients experienced metastatic relapse. Hierarchical clustering separated patients into five clusters with distinct prognosis based on pathways linked to immune activation, epithelial-to-mesenchymal transition and cell cycle. The immune microenvironment of the residual disease was significantly different between patients who experienced relapse compared to those who did not, the latter having significantly more effector antitumoral immune cells, with significant differences in lymphoid subpopulations. We selected eight genes linked to immunity (BLK, GZMM, CXCR6, LILRA1, SPIB, CCL4, CXCR4, SLAMF7) to develop a transcriptomic signature which could predict relapse in our cohort. This signature was validated in two external cohorts (KMplot and METABRIC).Conclusions Lack of immune activation after NACT is associated with a high risk of distant relapse. We propose a prognostic signature based on immune infiltrate that could lead to targeted therapeutic strategies to improve patient prognosis.

【 授权许可】

CC BY|CC BY-NC-ND